REGN5093
Phase 2 small_molecule active
Quick answer
REGN5093 for MET-altered non-small cell lung cancer (NSCLC) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- MET-altered non-small cell lung cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active